GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (NAS:FENC) » Definitions » Pretax Margin %

Fennec Pharmaceuticals (Fennec Pharmaceuticals) Pretax Margin % : -27.55% (As of Dec. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Fennec Pharmaceuticals Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Fennec Pharmaceuticals's Pre-Tax Income for the three months ended in Dec. 2023 was $-2.68 Mil. Fennec Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $9.74 Mil. Therefore, Fennec Pharmaceuticals's pretax margin for the quarter that ended in Dec. 2023 was -27.55%.

The historical rank and industry rank for Fennec Pharmaceuticals's Pretax Margin % or its related term are showing as below:

FENC' s Pretax Margin % Range Over the Past 10 Years
Min: -10640.37   Med: -1545.08   Max: -75.5
Current: -75.69


FENC's Pretax Margin % is ranked better than
58.23% of 1027 companies
in the Biotechnology industry
Industry Median: -175.8 vs FENC: -75.69

Fennec Pharmaceuticals Pretax Margin % Historical Data

The historical data trend for Fennec Pharmaceuticals's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Pretax Margin % Chart

Fennec Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -10,652.35 - -1,544.89 -75.50

Fennec Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -446.71 -360.88 -163.73 -28.66 -27.55

Competitive Comparison of Fennec Pharmaceuticals's Pretax Margin %

For the Biotechnology subindustry, Fennec Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fennec Pharmaceuticals's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's Pretax Margin % falls into.



Fennec Pharmaceuticals Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Fennec Pharmaceuticals's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-16.045/21.252
=-75.50 %

Fennec Pharmaceuticals's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-2.682/9.735
=-27.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fennec Pharmaceuticals  (NAS:FENC) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Fennec Pharmaceuticals Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Fennec Pharmaceuticals (Fennec Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Executives
Robert Andrade officer: Chief Financial Officer C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703
Rosty Raykov director, officer: Chief Executive Officer C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703
Chris A Rallis director C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Adrian Haigh director 83 ANGLESSA ROAD, BALLSBRIDGE, DUBLIN L2 D04H27
Marco Maria Brughera director VIALE STEFINI 14, MILANO L6 00000
Khalid Islam director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Shubh Goel officer: Chief Commercial Officer 1100 MAXWELL, #522, HOBOKEN NJ 07030
Southpoint Capital Advisors Lp 10 percent owner 1114 AVENUE OF THE AMERICAS, 22ND FLOOR, NEW YORK NY 10036
Spa Essetifin 10 percent owner VIA SUDAFRICA 20, ROME L6 00144
Jodi A Cook director PO BOX 816, NEWTOWN PA 08540
Manchester Management Pr, Llc 10 percent owner 3 WEST HILL PLACE, BOSTON MA 02114
Francesca Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Paolo Cavazza 10 percent owner VIA TESSERETE, 10, LUGANO V8 V8
Silvia Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040
Enrico Cavazza 10 percent owner VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040